H.C. Wainwright downgraded Alpine Immune Sciences to Neutral from Buy with a $65 price target after the company entered a definitive agreement to be acquired by Vertex Pharmaceuticals (VRTX) for $4.9B or $65 per share.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALPN: